Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma

Clin Lung Cancer. 2020 Jan;21(1):e25-e29. doi: 10.1016/j.cllc.2019.10.002. Epub 2019 Oct 13.
No abstract available

Keywords: EML4-ALK; EML4-ALK variants; Non–small-cell lung cancer; Tandem atypical propeller EML domain; Tyrosine kinase inhibitor.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Aged
  • Anaplastic Lymphoma Kinase / genetics*
  • Crizotinib / administration & dosage*
  • Gene Rearrangement*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Protein Kinase Inhibitors / administration & dosage*
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase